Glucagon

Limits on what this shows

• Key negative/null findings: A separate, decades-older body of animal literature shows the opposite functional direction at the acute level: Pegorier JP et al, "Induction of ketogenesis and fatty acid oxidation by glucagon and cyclic AMP in cultured hepatocytes from rabbit fetuses," 1989, PMID 2557835, and Zammit VA, "The effect of glucagon treatment... on the rates of oxidation of octanoyl-L-carnitine and octanoate by isolated liver mitochondria," 1980, PMID 7470052, both show glucagon acutely activating mitochondrial fatty-acid oxidation via cAMP-driven carnitine palmitoyltransferase I regulation. This is glucagon's own intended counter-regulatory action, mobilizing fuel during hypoglycemia, and per this project's rule against filing a drug's own intended pharmacologic effect as a nutrient-style deficiency, it is not itself graded here as a burden finding; it is recorded to explain why this entry should not be read as "glucagon always harms mitochondria."
• At-risk subgroups: The Yang 2019 model is chronic hyperglucagonemia, as occurs with sustained elevated endogenous glucagon in poorly controlled diabetes, not acute exogenous rescue dosing. This review located no study of repeated therapeutic glucagon administration and hepatic mitochondrial biogenesis.

Regulatory status

Not addressed in either label reviewed.

Population evidence

Yang W, Yan H, Pan Q, Shen JZ, Zhou F, Wu C, Sun Y, Guo S, "Glucagon regulates hepatic mitochondrial function and biogenesis through FOXO1," 2019, PMID 31026811. Mouse hepatocytes and db/db diabetic mice (chronic hyperglucagonemia model), reconstructed from OpenAlex's indexed abstract (PubMed and Europe PMC article pages returned no extractable content during this review). Glucagon reduced hepatic heme production and suppressed respiratory complex III and IV components in a FOXO1-dependent manner; the effect was largely reversed by hepatocyte-specific Foxo1 deletion. Glucagon also reduced expression of the mitochondrial biogenesis regulators NRF1, TFAM, and MFN2, again FOXO1-dependent; these regulators were found downregulated in the livers of diabetic db/db mice.

Mechanism

FOXO1-dependent transcriptional suppression of respiratory-chain and mitochondrial-biogenesis genes under sustained glucagon/cAMP signaling.

Counter-evidence held on record

The acute fatty-acid-oxidation literature runs in the opposite functional direction from the chronic FOXO1 finding, and both are real, drug-specific results; the discrepancy reflects different exposure patterns (acute allosteric activation of existing oxidative machinery versus chronic transcriptional suppression of new mitochondrial biogenesis), not a contradiction requiring resolution here. This entry describes a chronic hyperglucagonemia disease model, a poor match to the single-dose or short diagnostic course this drug is actually approved and typically used for, and should not be read as a caution about ordinary rescue dosing. It shares its entire evidentiary basis with the Iron and ATP production entries below; see Overlap map.

Limits on what this shows

• Key negative/null findings: Direct PubMed searches for "glucagon oxidative stress" and "glucagon reactive oxygen species liver" returned no drug-specific hits; results were dominated by GLP-1 (glucagon-like peptide-1) receptor agonist studies, a mechanistically distinct drug class using a different receptor, which were not extrapolated onto glucagon here. One tangentially related rat-liver-perfusion study, Messner J, Graf J, "Reactive oxygen species facilitate the insulin-dependent inhibition of glucagon-induced glucose production in the isolated perfused rat liver," 2008, PMID 18998075, examines how reactive oxygen species modulate glucagon's own glucose-production signaling, the reverse causal direction from what this entry grades, and per this project's directionality rule is not used as supporting evidence.
• At-risk subgroups: Not established; rat and isolated-hepatocyte data only, no human replication located.

Regulatory status

Not addressed in either label reviewed.

Population evidence

Cousins RJ, Coppen DE, "Regulation of liver zinc metabolism and metallothionein by cAMP, glucagon and glucocorticoids and suppression of free radicals by zinc," Experientia Suppl, 1987, PMID 2822465. Rat / isolated hepatocyte model, reconstructed from OpenAlex's indexed abstract. Glucagon, alongside dibutyryl cAMP and dexamethasone, substantially raised hepatic metallothionein mRNA (roughly sevenfold) and correlated with a transient reduction in serum zinc (see Zinc entry below). Using spin-trapping electron spin resonance, the elevated hepatic zinc reduced free-radical formation and malondialdehyde (lipid-peroxidation marker) generation under an oxidative challenge.

Mechanism

Glucagon/cAMP-driven hepatic metallothionein induction raises intracellular zinc availability; zinc's own antioxidant and free-radical-scavenging chemistry is the protective mechanism demonstrated. Glucagon itself has no direct antioxidant action shown in this or any other source located.

Counter-evidence held on record

This is an indirect, zinc-mediated mechanism, not glucagon itself acting as an antioxidant, and it was demonstrated only in rats and isolated hepatocytes. Because the evidence located trends protective rather than depleting, no popular claim about glucagon causing oxidative stress could be graded here at any tier, and none was found circulating. This entry exists specifically because a real, drug-adjacent redox signal ran in the opposite direction from a "depletion" framing, graded on the same tier scale per this project's convention for reverse-direction findings; it shares its zinc-mediated mechanism with the Zinc entry below (see Overlap map) and should not be double-counted with it.

Limits on what this shows

• Key negative/null findings: The same Brandao-Neto 1988 study found no significant change in urinary copper (or other measured urinary ions), arguing against simple renal wasting as the mechanism and favoring a hepatic redistribution or altered-efflux explanation over a straightforward body loss.
• At-risk subgroups: Cannot be determined from an n=5, single-dose study; no subgroup analysis exists. Repeated or continuous glucagon dosing (for example, high-dose infusion protocols used in refractory beta-blocker or calcium-channel-blocker poisoning) is the plausible higher-exposure setting, though it was not directly studied for copper.

Regulatory status

Not addressed in the FDA glucagon label reviewed; no copper-related warning or monitoring requirement exists in labeling.

Population evidence

Brandao-Neto J et al, "Metabolic effects of glucagon on plasma and urine zinc, copper, calcium and magnesium levels," Braz J Med Biol Res, 1988, PMID 3179577. Human, n=5 healthy adults, single-arm, 2.0 mg intravenous glucagon infusion over 120 minutes. Verbatim, reconstructed from the indexed abstract (original SciELO journal page returned a 403 error during this review): "A decrease in plasma copper was observed with no significant change in urine ion concentrations." No confidence interval or percent magnitude is given in the accessible abstract text; the sample is small (n=5) and single-dose.

Mechanism

Hilario-Souza E et al, "Modulation of hepatic copper-ATPase activity by insulin and glucagon involves protein kinase A (PKA) signaling pathway," Biochim Biophys Acta, 2016, PMID 27523629. Title-confirmed only; the full abstract could not be retrieved during this review (OpenAlex returned no indexed abstract text and the PubMed article page returned no extractable content). The title indicates glucagon signals through PKA to modulate hepatic copper-ATPase (ATP7B), the transporter governing biliary copper excretion and ceruloplasmin loading, a plausible hepatic mechanism consistent with the human plasma-copper finding above, though the direction of ATP7B modulation itself is not confirmed from the title alone.

Counter-evidence held on record

This finding rests on a single small (n=5) acute-exposure human study that this review could not locate a replication of; the original journal page could not be opened to check full methodology, assay technique, or statistical handling beyond the indexed abstract sentence quoted above. This describes an acute, single-dose plasma shift, not a chronic body-copper deficit, and it does not support copper supplementation around glucagon rescue dosing. The boundary condition for this orange grade is the acute, single-IV-dose exposure window studied; ordinary intramuscular or subcutaneous rescue dosing in the field was not the route studied here.

Limits on what this shows

• Key negative/null findings: PubMed searches for "glucagon iron metabolism" and "glucagon heme iron ferrochelatase OR hepcidin" returned no drug-specific hits beyond general iron- and hepcidin-biology literature unrelated to glucagon; no case report or human study of glucagon and iron status was located anywhere in this review.
• At-risk subgroups: Cannot be determined; same chronic hyperglucagonemia model caveat as Mitochondrial burden.

Regulatory status

Not addressed in either label reviewed.

Population evidence

Yang W et al, PMID 31026811 (same source as Mitochondrial burden above). Mouse hepatocytes / db/db mice: glucagon reduced heme production in a FOXO1-dependent manner, alongside suppression of respiratory complexes III and IV, both of which are heme-containing (cytochrome bc1 and cytochrome c oxidase).

Mechanism

FOXO1-dependent transcriptional effects on heme biosynthesis and heme-dependent respiratory-complex assembly under chronic hyperglucagonemia; not established as a direct effect on iron absorption, storage, or erythropoiesis.

Counter-evidence held on record

This entry rests on a single indirect endpoint (heme synthesis, a downstream consequence of both iron availability and porphyrin synthesis together, not a direct iron-status marker) from a paper primarily about mitochondrial respiratory function, not iron specifically. Graded yellow rather than left ungraded because genuine Tier B evidence touches iron-relevant biology, but this is the weakest-supported entry in this dossier for exactly that reason, and it shares its entire evidentiary basis with the Mitochondrial burden and ATP production entries; see Overlap map. No case for iron supplementation or iron-status monitoring follows from this entry alone.

Limits on what this shows

• Why no grade: Two differently phrased PubMed searches ("glucagon gut microbiome," 733 results; "glucagon microbiome intestinal bacteria," thousands of results) were reviewed at the title level; every on-topic result used GLP-1 (glucagon-like peptide-1) receptor agonists, incretin hormones, or unrelated gut-hormone/microbiome topics, never exogenous or therapeutic glucagon itself. GLP-1 receptor agonists act through a different receptor (GLP-1R, not the glucagon receptor GCGR) and are not a valid class-level stand-in for glucagon under this project's cohort rule, so this large body of GLP-1 microbiome literature was not extrapolated onto glucagon. Mechanistically, glucagon's injectable and intranasal delivery routes involve essentially no GI luminal exposure (see PK basis above), which independently limits the plausibility of a direct microbiome mechanism of the kind documented for orally dosed drugs. Drugs.com and RxList consumer pages were reviewed for the circulating-claim audit and contained no microbiome-related claim about glucagon.

Channels tried

PubMed (2 clean, unblocked search-listing queries across two phrasings, both returning only off-target GLP-1/incretin results at the title level), consumer-claim audit (drugs.com, RxList, no claim found), PK-based mechanistic reasoning (no GI luminal exposure route for any approved formulation). Europe PMC and Semantic Scholar were attempted repeatedly for this and other categories throughout this review but returned HTTP 429 on every attempt and could not be used specifically for this category; NCBI Bookshelf/StatPearls returned a bot-verification challenge page on every attempt and could not be used either.

Genuine gap vs. tooling-limited

Predominantly genuine. Two independently phrased PubMed queries returned large, clean, unblocked result sets that were topically off-target rather than empty or error pages, a meaningfully stronger signal than a block; combined with the mechanistic implausibility from this drug's delivery routes, this supports a real absence of drug-specific evidence rather than a search failure. The unreachable Europe PMC and Semantic Scholar channels are a disclosed, residual tooling limitation that a future revision should re-check, though the PubMed signal obtained here was clean rather than blocked.

Limits on what this shows

• Key negative/null findings: A direct PubMed search combining glucagon with hemoglobin, hematocrit, and erythropoiesis returned no glucagon-specific results at all (generic hematology literature only, unrelated to glucagon). This review found no evidence at any tier that glucagon affects hemoglobin, red-cell mass, or arterial oxygen content.
• At-risk subgroups: Patients with limited cardiopulmonary reserve, per the labeled cardiac-safety caution above.

Regulatory status

The label separately warns, for diagnostic use, that glucagon "may increase myocardial oxygen demand, blood pressure, and pulse rate which may be life-threatening in patients with cardiac disease," a labeled cardiac-safety caution touching this category's oxygen-demand dimension, not a nutrient finding.

Population evidence

Davidson IWF, Salter JM, Best CH, "Calorigenic Action of Glucagon," Nature, 1957, 180:1124, DOI 10.1038/1801124a0. Historical animal physiology; title/bibliographic-level only, full text not accessible during this review. Weiser PC, Grande F, "Calorigenic Effects of Glucagon and Epinephrine in Anesthetized Dogs," Exp Biol Med, 1974, 145:912-917, DOI 10.3181/00379727-145-37923. Animal (dog); title/bibliographic-level only, full text not accessible during this review.

Mechanism

Glucagon's cAMP-driven stimulation of hepatic glycogenolysis, gluconeogenesis, and lipolysis increases metabolic rate and therefore oxygen utilization; this is the same counter-regulatory action that makes glucagon effective as a hypoglycemia rescue agent, not a drop in oxygen-carrying capacity or oxygen delivery.

Counter-evidence held on record

Both calorigenic sources are historical, title-level citations that could not be opened for full methodological detail during this review. Per this project's explicit governance rule, a drug's own intended metabolic/hemodynamic mechanism is not an oxygen-delivery deficiency. This entry is retained at yellow, framed strictly as a mechanism clarification plus a labeled cardiac caution, and must never be read or published as a claim that glucagon depletes oxygen delivery or requires nutrient correction.

Limits on what this shows

• Key negative/null findings: PubMed searches for "glucagon ATP production liver" and adjacent "glucagon mitochondria" phrasings returned no study directly quantifying ATP yield or mitochondrial respiration rate after glucagon exposure, in humans or animals.
• At-risk subgroups: Same chronic hyperglucagonemia model caveat as Mitochondrial burden and Iron; not established for acute rescue dosing.

Regulatory status

Not addressed in either label reviewed.

Population evidence

Yang W et al, PMID 31026811 (same source as Mitochondrial burden and Iron above). Mouse hepatocytes / db/db mice: FOXO1-dependent suppression of respiratory complexes III and IV.

Mechanism

Respiratory complex III (cytochrome bc1) and complex IV (cytochrome c oxidase) are obligate components of oxidative phosphorylation; FOXO1-dependent suppression of their expression is mechanistically expected to lower ATP synthesis capacity, though ATP output itself was not directly measured in the cited study.

Counter-evidence held on record

This entry is an inference one step removed from a direct ATP measurement: complex expression, not electron-transport flux or ATP yield, is what was actually measured in the cited study. This entry shares its entire evidentiary basis with the Mitochondrial burden and Iron entries above (see Overlap map) and should not be counted as independent confirmation alongside them. No energy-supplement recommendation follows from this entry.